202 related articles for article (PubMed ID: 9649229)
1. Integration of surgery and systemic therapy: results and principles of integration.
Donohue JP; Leviovitch I; Foster RS; Baniel J; Tognoni P
Semin Urol Oncol; 1998 May; 16(2):65-71. PubMed ID: 9649229
[TBL] [Abstract][Full Text] [Related]
2. Surgery for testicular cancer: indication, results and technical aspects.
Khouni H; Ghozzi S; Ramzi K; Smaali CH; Majed H; Ben Rais N
Tunis Med; 2005 Dec; 83 Suppl 12():78-83. PubMed ID: 16430075
[TBL] [Abstract][Full Text] [Related]
3. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
5. The role of retroperitoneal lymph node dissection in the management of testicular cancer.
Stephenson AJ; Sheinfeld J
Urol Oncol; 2004; 22(3):225-33; discussion 234-5. PubMed ID: 15271322
[TBL] [Abstract][Full Text] [Related]
6. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
7. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.
Geldart TR; Gale J; McKendrick J; Kirby J; Mead G
BJU Int; 2006 Aug; 98(2):353-8. PubMed ID: 16879677
[TBL] [Abstract][Full Text] [Related]
8. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
[TBL] [Abstract][Full Text] [Related]
9. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
10. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer.
Heidenreich A; Ohlmann C; Hegele A; Beyer J
Eur Urol; 2005 Jan; 47(1):64-71. PubMed ID: 15582251
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of retroperitoneal lymph node dissection for patients with advanced germ cell tumors].
Okamura K; Yuba H; Nishimura T; Mizutani K; Takashi M; Gotoh M; Ono Y; Ohshima S
Hinyokika Kiyo; 1999 Feb; 45(2):95-101. PubMed ID: 10212781
[TBL] [Abstract][Full Text] [Related]
12. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
13. Primary chemotherapy: how does it compare with surgery?
Horwich A
Semin Urol Oncol; 1996 Feb; 14(1):34-5. PubMed ID: 8833387
[TBL] [Abstract][Full Text] [Related]
14. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
15. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
[TBL] [Abstract][Full Text] [Related]
16. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
17. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
[TBL] [Abstract][Full Text] [Related]
18. Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non-seminomatous germ cell cancer patients.
Goepel M; Recker F; Otto T; Krege S; Rübben H
Urol Int; 1996; 57(4):209-12. PubMed ID: 8961487
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience.
Steiner H; Peschel R; Janetschek G; Höltl L; Berger AP; Bartsch G; Hobisch A
Urology; 2004 Mar; 63(3):550-5. PubMed ID: 15028456
[TBL] [Abstract][Full Text] [Related]
20. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
